The short answer: Uveal (choroidal) melanoma is a rare eye cancer that, once it metastasizes — usually to the liver — has limited treatment options and a poor prognosis. End-of-life care focuses on managing liver-dominant metastatic disease, controlling pain, maintaining quality of life, and supporting patients through a diagnosis that often comes as a devastating surprise.

What to Expect With Uveal (Choroidal) Melanoma End-of-Life Care

Uveal melanoma arises from melanocytes in the uveal tract of the eye (iris, ciliary body, choroid). Though rare (~5 cases per million annually), it has a high metastatic rate — approximately 50% of patients develop metastases, most commonly to the liver. Once metastatic, median survival has historically been 6-12 months, though newer treatments are extending this.

Unique Challenges of Metastatic Uveal Melanoma

Unlike cutaneous melanoma, uveal melanoma does not respond well to checkpoint immunotherapy (PD-1/PD-L1 inhibitors). The molecular drivers are different (GNA11/GNAQ mutations). This means patients who hear "melanoma" and are told immunotherapy isn't effective face a devastating gap in treatment options.

Tebentafusp (Kimmtrak) — the first FDA-approved treatment specifically for metastatic uveal melanoma (2022) — has shown improved survival in HLA-A*02:01 positive patients. Clinical trials remain the best option for most patients.

Liver Metastasis: The Central Challenge

Liver metastases from uveal melanoma can cause significant symptoms: right upper quadrant pain, nausea, early satiety, jaundice (as disease progresses), fatigue, and eventually liver failure. Palliative liver-directed therapies (TACE, TARE/Y90) may extend liver function and quality of life even when systemic disease progresses.

Symptom Management Priorities

Pain from liver capsule distension is managed with scheduled opioids and steroids to reduce inflammation. Nausea requires antiemetics. Ascites may develop requiring drainage. Jaundice indicates advanced liver dysfunction and signals proximity to end of life.

Psychological Impact of Uveal Melanoma

Many uveal melanoma patients have already experienced one loss — the eye or visual function — from primary treatment. Facing metastatic diagnosis can feel like a second devastating blow. The rarity of the disease, the poor response to standard immunotherapy, and the limited treatment options can create profound psychological distress and isolation.

End-of-Life Care Planning

Given the liver-dominant nature and relatively predictable trajectory, early advance care planning and hospice enrollment are especially valuable. Death doulas familiar with uveal melanoma can provide psychosocial support specific to this uniquely difficult diagnosis.

Frequently Asked Questions

What is uveal melanoma?

Uveal melanoma is a rare cancer arising from melanocytes in the uveal tract of the eye (choroid, ciliary body, or iris). It's the most common primary eye cancer in adults. The primary tumor is treated with radiation (proton beam or plaque radiotherapy) or surgery; however, approximately 50% of patients develop distant metastases, most commonly to the liver.

Why doesn't immunotherapy work for uveal melanoma?

Unlike cutaneous melanoma, uveal melanoma is driven by different genetic mutations (GNA11/GNAQ) and has a different tumor microenvironment. The PD-L1 pathway targeted by checkpoint immunotherapy plays a less central role, so drugs like pembrolizumab and nivolumab that work well for cutaneous melanoma have minimal effectiveness for uveal melanoma. Tebentafusp (Kimmtrak) is the first approved therapy specifically targeting metastatic uveal melanoma.

What are symptoms of metastatic uveal melanoma?

Metastatic uveal melanoma symptoms depend on where it has spread. Liver metastases (most common) cause right upper quadrant pain, nausea, fatigue, weight loss, early satiety, and eventually jaundice. Lung metastases may cause shortness of breath. Bone metastases cause bone pain. Many patients have no symptoms when metastases are first detected on surveillance imaging.

What is the prognosis for metastatic uveal melanoma?

The prognosis for metastatic uveal melanoma has historically been poor, with median survival of 6-12 months after metastasis. Tebentafusp (approved 2022) has shown improved overall survival for eligible patients. Liver-directed therapies (TACE, Y90) can extend liver function. Clinical trials offer access to emerging treatments. Individual prognosis varies widely.

When should hospice be considered for uveal melanoma?

Hospice is appropriate when uveal melanoma has stopped responding to all available treatments, when the patient's performance status has significantly declined, or when goals of care shift toward comfort. Given the often rapid progression once liver disease becomes significant, early conversations about hospice allow better planning and more meaningful end-of-life time.

Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.